Dr.HeidiM.Mansour

From OpenWetWare

(Difference between revisions)
Jump to: navigation, search
(Journal Publications *Corresponding Author*)
(Journal Publications *Corresponding Author*)
(37 intermediate revisions not shown.)
Line 10: Line 10:
1703 E. Mabel St.
1703 E. Mabel St.
-
Office 434/Lab 435 Skaggs PharmSci Ctr
+
Office 434/Lab 435 Skaggs Pharmaceutical Sciences Center
-
Tucson, AZ 85721-0207.
+
Tucson, AZ 85721-0202.
Email: mansour@pharmacy.arizona.edu
Email: mansour@pharmacy.arizona.edu
Line 24: Line 24:
== Websites ==
== Websites ==
-
Research: [http://www.pharmacy.arizona.edu/directory/heidi-mansour-phd]
+
Research & Education: [http://www.pharmacy.arizona.edu/directory/heidi-mansour-phd]
-
Graduate Program:[http://graduate.pharmacy.arizona.edu/content/faculty-2]
+
Graduate Program-Faculty Member:[http://graduate.pharmacy.arizona.edu/content/faculty-2]
-
Institute of the Environment: [http://environment.arizona.edu/heidi-mansour]
+
Institute of the Environment-Affiliated Faculty Member: [http://environment.arizona.edu/heidi-mansour]
 +
NCI Comprehensive Cancer Center[http://azcc.arizona.edu/about]-Associate Member: [http://azcc.arizona.edu/profile/heidi-mansour-0]
-
Google Scholar: [http://scholar.google.com/citations?hl=en&user=w2MFixQAAAAJ&sortby=pubdate&view_op=list_works&pagesize=100]
+
Google Scholar Publications: [http://scholar.google.com/citations?hl=en&user=w2MFixQAAAAJ&sortby=pubdate&view_op=list_works&pagesize=100]
-
LinkedIn: [http://www.linkedin.com/in/heidimansour]
+
PubMed Publications: [http://www.ncbi.nlm.nih.gov/pubmed/?term=mansour+hm]
-
Research Gate: [https://www.researchgate.net/profile/Heidi_Mansour/info/?ev=prf_info]
+
LinkedIn Profile: [http://www.linkedin.com/in/heidimansour]
 +
Research Gate Profile: [https://www.researchgate.net/profile/Heidi_Mansour/info/?ev=prf_info]
College of Pharmacy:  
College of Pharmacy:  
Line 174: Line 176:
==Journal Publications *Corresponding Author* ==
==Journal Publications *Corresponding Author* ==
 +
 +
 +
'''== 2001-2009 =='''
 +
1. '''Mansour H.''', Wang D.-S., Chen C.-S., and Zografi G. ''Comparison of Bilayer and Monolayer Properties of Phospholipid Systems Containing Dipalmitoylphosphatidylglycerol and Dipalmitoylphosphatidylinositol.'' [[Langmuir]] (2001) 17 (21) October 16: 6622-6632. (Impact Factor: 4.187)[http://pubs.acs.org/doi/abs/10.1021/la0108454]
1. '''Mansour H.''', Wang D.-S., Chen C.-S., and Zografi G. ''Comparison of Bilayer and Monolayer Properties of Phospholipid Systems Containing Dipalmitoylphosphatidylglycerol and Dipalmitoylphosphatidylinositol.'' [[Langmuir]] (2001) 17 (21) October 16: 6622-6632. (Impact Factor: 4.187)[http://pubs.acs.org/doi/abs/10.1021/la0108454]
Line 188: Line 194:
7. Xu, Z., '''Mansour, H.M.''', Mulder, T., McLean, R., Langridge, J., and Hickey, A.J. ''Comparative Dispersion Study of Dry Powder Aerosols of Albuterol Sulfate/Lactose Monohydrate and Cromolyn Sodium/Lactose Monohydrate Delivered by Standardized Entrainment Tubes.'' [[Respiratory Drug Delivery]] (2008) 3: 897-900. [http://www.rddonline.com/publications/articles/article.php?ArticleID=1265&return=1]
7. Xu, Z., '''Mansour, H.M.''', Mulder, T., McLean, R., Langridge, J., and Hickey, A.J. ''Comparative Dispersion Study of Dry Powder Aerosols of Albuterol Sulfate/Lactose Monohydrate and Cromolyn Sodium/Lactose Monohydrate Delivered by Standardized Entrainment Tubes.'' [[Respiratory Drug Delivery]] (2008) 3: 897-900. [http://www.rddonline.com/publications/articles/article.php?ArticleID=1265&return=1]
-
8. '''*Mansour H.M.*''', Damodaran S., and Zografi G.'' Characterization of the In Situ Structural and Interfacial Properties of the Cationic Hydrophobic Heteropolypeptide, KL4, in Lung Surfactant Bilayer and Monolayer Models at the Air-Water Interface: Implications for Pulmonary Surfactant Delivery.'' [[Molecular Pharmaceutics]] (2008) 5 (5) October 6: 681-695. (Impact Factor: 4.782)[http://pubs.acs.org/doi/abs/10.1021/mp700123p]
+
8. '''*Mansour H.M.*''', Damodaran S., and Zografi G.'' Characterization of the In Situ Structural and Interfacial Properties of the Cationic Hydrophobic Heteropolypeptide, KL4, in Lung Surfactant Bilayer and Monolayer Models at the Air-Water Interface: Implications for Pulmonary Surfactant Delivery.'' [[Molecular Pharmaceutics]] (2008) 5 (5) October 6: 681-695. (Impact Factor: 4.57)[http://pubs.acs.org/doi/abs/10.1021/mp700123p]
9. '''*Mansour, H.M.*''', Rhee, Y.S., and Wu, X. ''Nanomedicine in Pulmonary Delivery.''  [[International Journal of Nanomedicine]] (2009) 4 December: 299-319.(Impact Factor: 3.463)[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2802043/pdf/ijn-4-299.pdf]
9. '''*Mansour, H.M.*''', Rhee, Y.S., and Wu, X. ''Nanomedicine in Pulmonary Delivery.''  [[International Journal of Nanomedicine]] (2009) 4 December: 299-319.(Impact Factor: 3.463)[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2802043/pdf/ijn-4-299.pdf]
 +
 +
 +
'''== 2010 =='''
10. Xu, Z., '''Mansour, H.M.''', Mulder, T., McLean, R., Langridge, J., and Hickey, A.J. ''Dry Powder Aerosols Generated by Standardized Entrainment Tubes from Drug Blends with Lactose Monohydrate: 1. Albuterol Sulfate and Disodium Cromoglycate.'' [[Journal of Pharmaceutical Sciences]] (2010) 99 (8) March 2: 3398-3414.(Impact Factor: 3.13)[http://onlinelibrary.wiley.com/doi/10.1002/jps.22107/abstract]
10. Xu, Z., '''Mansour, H.M.''', Mulder, T., McLean, R., Langridge, J., and Hickey, A.J. ''Dry Powder Aerosols Generated by Standardized Entrainment Tubes from Drug Blends with Lactose Monohydrate: 1. Albuterol Sulfate and Disodium Cromoglycate.'' [[Journal of Pharmaceutical Sciences]] (2010) 99 (8) March 2: 3398-3414.(Impact Factor: 3.13)[http://onlinelibrary.wiley.com/doi/10.1002/jps.22107/abstract]
Line 207: Line 216:
17. Wu, X., Li, X., and  '''*Mansour, H.M.*'''  ''Surface Analytical Techniques in Solid-State Particle Characterization: Implications for Predicting Performance in Dry Powder Inhalers. Invited Paper.'' [[KONA Powder and Particle Journal]] (2010) 28: 3-19.  [http://www.kona.or.jp/search/28_003.pdf]
17. Wu, X., Li, X., and  '''*Mansour, H.M.*'''  ''Surface Analytical Techniques in Solid-State Particle Characterization: Implications for Predicting Performance in Dry Powder Inhalers. Invited Paper.'' [[KONA Powder and Particle Journal]] (2010) 28: 3-19.  [http://www.kona.or.jp/search/28_003.pdf]
 +
 +
 +
'''== 2011 =='''
18. Xu, Z., '''Mansour, H.M.''', and Hickey, A.J. ''Particle Interactions in Dry Powder Inhaler Unit Processes.'' [[Journal of Adhesion Science and Technology: Special Issue on Adhesion Aspects in Pharmaceutical Sciences]] (2011): 25 (4/5) 451-482. (Impact Factor: 1.175)[http://www.ingentaconnect.com/content/vsp/ast/2011/00000025/F0020004/art00009]
18. Xu, Z., '''Mansour, H.M.''', and Hickey, A.J. ''Particle Interactions in Dry Powder Inhaler Unit Processes.'' [[Journal of Adhesion Science and Technology: Special Issue on Adhesion Aspects in Pharmaceutical Sciences]] (2011): 25 (4/5) 451-482. (Impact Factor: 1.175)[http://www.ingentaconnect.com/content/vsp/ast/2011/00000025/F0020004/art00009]
Line 227: Line 239:
27. Li, X. and  '''*Mansour, H.M.*''' ''Physicochemical Characterization and Water Vapor Absorption of Organic Solution Advanced Spray Dried Trehalose Microparticles and Nanoparticles for Targeted Dry Powder Pulmonary Inhalation Delivery.''  [[AAPS PharmSciTech: Special Theme Issue: Advances in Pharmaceutical Excipients Research and Use: Novel Materials, Functionalities and Testing]] (2011)12(4):1420-1430. (Impact Factor: 1.584)[http://www.pharmagateway.net/ArticlePage.aspx?DOI=10.1208/s12249-011-9704-0] [http://www.box.com/shared/0omofu03jsg2s5vs8yym]
27. Li, X. and  '''*Mansour, H.M.*''' ''Physicochemical Characterization and Water Vapor Absorption of Organic Solution Advanced Spray Dried Trehalose Microparticles and Nanoparticles for Targeted Dry Powder Pulmonary Inhalation Delivery.''  [[AAPS PharmSciTech: Special Theme Issue: Advances in Pharmaceutical Excipients Research and Use: Novel Materials, Functionalities and Testing]] (2011)12(4):1420-1430. (Impact Factor: 1.584)[http://www.pharmagateway.net/ArticlePage.aspx?DOI=10.1208/s12249-011-9704-0] [http://www.box.com/shared/0omofu03jsg2s5vs8yym]
 +
 +
 +
'''== 2012 =='''
28. Hayes, D. Jr.,  Winkler, M.A., Kirkby, S., Capasso, P., '''Mansour, H.M.''' and Attili, A.K. ''Preprocedural Planning with Prospectively Triggered Multi-Detector Row CT Angiography prior to Bronchial Artery Embolization in Cystic Fibrosis Patients with Massive Hemoptysis.'' [[Lung]] (2012)190 (2)April:221-225.(Impact Factor: 2.062)[http://www.springerlink.com/content/y761114p7m62451m/]
28. Hayes, D. Jr.,  Winkler, M.A., Kirkby, S., Capasso, P., '''Mansour, H.M.''' and Attili, A.K. ''Preprocedural Planning with Prospectively Triggered Multi-Detector Row CT Angiography prior to Bronchial Artery Embolization in Cystic Fibrosis Patients with Massive Hemoptysis.'' [[Lung]] (2012)190 (2)April:221-225.(Impact Factor: 2.062)[http://www.springerlink.com/content/y761114p7m62451m/]
Line 234: Line 249:
30. Hayes, D. Jr., '''Mansour, H.M.''', Kirkby, S., and Phillips, A.B. ''Rapid Acute Onset of Bronchiolitis Obliterans Syndrome in a Lung Transplant Recipient After Respiratory Syncytial Virus Infection." [[Transplant Infectious Diseases]] (2012)14 (5): 548-550. [Impact Factor: 2.216][http://onlinelibrary.wiley.com/doi/10.1111/j.1399-3062.2012.00748.x/abstract;jsessionid=B6A3A133BAFC963F559C344343F14F9F.d03t04]
30. Hayes, D. Jr., '''Mansour, H.M.''', Kirkby, S., and Phillips, A.B. ''Rapid Acute Onset of Bronchiolitis Obliterans Syndrome in a Lung Transplant Recipient After Respiratory Syncytial Virus Infection." [[Transplant Infectious Diseases]] (2012)14 (5): 548-550. [Impact Factor: 2.216][http://onlinelibrary.wiley.com/doi/10.1111/j.1399-3062.2012.00748.x/abstract;jsessionid=B6A3A133BAFC963F559C344343F14F9F.d03t04]
-
31.Hayes, D Jr., Kirkby, S., McCoy, K.S., '''Mansour, H.M.''', Khosravi, M., Strawbridge, H., and Tobias, J.D. ''Reduction of Lipid-Laden Macrophage Index After Laproscopic Nissen Fundoplication in Cystic Fibrosis Patients After Lung Transplantation.'' [[Clinical Transplantation]] (2013) 27 (1): 121-125.(Impact Factor: 1.677) [http://onlinelibrary.wiley.com/doi/10.1111/ctr.12020/abstract]
+
31. Duan, J.H., '''Mansour, H.M.''', Zhang, Y.D., Deng, X.M., Zhao, J.F. ''Reversion of Multi-Drug Resistance by Co-Encapsulation of Doxorubicin and Curcumin in Chitosan/poly(butylcyanoacrylate) Nanoparticles.'' [[International Journal of Pharmaceutics]] (2012) 426 (1-2): 193-201. (Impact Factor: 3.458)[http://www.sciencedirect.com/science/article/pii/S0378517312000543?v=s5]
-
32. Duan, J.H., '''Mansour, H.M.''', Zhang, Y.D., Deng, X.M., Zhao, J.F. ''Reversion of Multi-Drug Resistance by Co-Encapsulation of Doxorubicin and Curcumin in Chitosan/poly(butylcyanoacrylate) Nanoparticles.'' [[International Journal of Pharmaceutics]] (2012) 426 (1-2): 193-201. (Impact Factor: 3.458)[http://www.sciencedirect.com/science/article/pii/S0378517312000543?v=s5]
+
32. Park, C.W., '''Mansour, H.M.''', Oh, T.O., Kim, J.Y., Ha, J.M., Lee, B.J., Chi, S.C., Rhee, Y.S., Park, E,S. "''Phase behavior of itraconazole-phenol mixtures and its pharmaceutical applications.''" [[International Journal of Pharmaceutics]] (2012) 436 (1-2):652-658.(Impact Factor: 3.458) [http://www.sciencedirect.com/science/article/pii/S0378517312007752]
-
33. Park, C.W., '''Mansour, H.M.''', Oh, T.O., Kim, J.Y., Ha, J.M., Lee, B.J., Chi, S.C., Rhee, Y.S., Park, E,S. "''Phase behavior of itraconazole-phenol mixtures and its pharmaceutical applications.''" [[International Journal of Pharmaceutics]] (2012) 436 (1-2):652-658.(Impact Factor: 3.458) [http://www.sciencedirect.com/science/article/pii/S0378517312007752]
+
33. Park, C.W., Rhee, Y.S., Vogt, F.G., Hayes, D Jr., Zwischenberger, J.B., DeLuca, P.P., and '''*Mansour, H.M.*''' ''Advances in Microscopy and Complementary Imaging Techniques to Assess the Fate of Drugs Ex-Vivo in Respiratory Drug Delivery. Invited Paper.'' [[Advanced Drug Delivery Reviews: Special Theme Issue-Computational and Visualization Approaches in Respiratory Delivery.]] (2012) 64 (4) March 30: 344-356. (Impact Factor: 12.888)[http://www.sciencedirect.com/science/article/pii/S0169409X11002298]
-
34. Park, C.W., Rhee, Y.S., Vogt, F.G., Hayes, D Jr., Zwischenberger, J.B., DeLuca, P.P., and '''*Mansour, H.M.*''' ''Advances in Microscopy and Complementary Imaging Techniques to Assess the Fate of Drugs Ex-Vivo in Respiratory Drug Delivery. Invited Paper.'' [[Advanced Drug Delivery Reviews: Special Theme Issue-Computational and Visualization Approaches in Respiratory Delivery.]] (2012) 64 (4) March 30: 344-356. (Impact Factor: 12.888)[http://www.sciencedirect.com/science/article/pii/S0169409X11002298]
+
34. Willis, M.L., Hayes, D Jr., and '''*Mansour, H.M.*''' ''Therapeutic Liposomal Dry Powder Inhalation Aerosols for Targeted Lung Delivery.'' [[Lung]] (2012) 190 (3): 251-262.(Impact Factor: 2.062)[http://www.springerlink.com/content/a833780030np6468/] [http://www.box.com/shared/2027z21x6myctpztvsk0]
-
35. Willis, M.L., Hayes, D Jr., and '''*Mansour, H.M.*''' ''Therapeutic Liposomal Dry Powder Inhalation Aerosols for Targeted Lung Delivery.'' [[Lung]] (2012) 190 (3): 251-262.(Impact Factor: 2.062)[http://www.springerlink.com/content/a833780030np6468/] [http://www.box.com/shared/2027z21x6myctpztvsk0]
+
35.'''*Mansour, H.M.*''' "''Aerosol Formulation Issues.''" [[Pediatric Pulmonology]] (2012) 47 (35):149-151. (Impact Factor: 2.533) [http://onlinelibrary.wiley.com/doi/10.1002/ppul.22681/abstract]
-
36.'''*Mansour, H.M.*''' "''Aerosol Formulation Issues.''" [[Pediatric Pulmonology]] (2012) 47 (35):149-151. (Impact Factor: 2.533) [http://onlinelibrary.wiley.com/doi/10.1002/ppul.22681/abstract]
 
-
37. Meenach, S.A. Vogt,F.G., Anderson, K.W., Hilt, J.Z., McGarry,R.C., and  '''*Mansour, H.M.*'''. ''Design, Physicochemical Characterization, and Optimization of Organic Solution Advanced Spray-Dried Inhalable Dipalmitoylphosphatidylcholine (DPPC) and Dipalmitoylphosphatidylethanolamine Poly(Ethylene Glycol) (DPPE-PEG) Microparticles and Nanoparticles for Targeted Respiratory Nanomedicine Delivery as Dry Powder Inhalation Aerosols.'' [[International Journal of Nanomedicine]] (2013) 8:275-293.(Impact Factor: 3.463)[http://www.dovepress.com/getfile.php?fileID=14947]
+
'''== 2013 =='''
 +
 
 +
36. Meenach, S.A. Vogt,F.G., Anderson, K.W., Hilt, J.Z., McGarry,R.C., and  '''*Mansour, H.M.*'''. ''Design, Physicochemical Characterization, and Optimization of Organic Solution Advanced Spray-Dried Inhalable Dipalmitoylphosphatidylcholine (DPPC) and Dipalmitoylphosphatidylethanolamine Poly(Ethylene Glycol) (DPPE-PEG) Microparticles and Nanoparticles for Targeted Respiratory Nanomedicine Delivery as Dry Powder Inhalation Aerosols.'' [[International Journal of Nanomedicine]] (2013) 8:275-293.(Impact Factor: 3.463)[http://www.dovepress.com/getfile.php?fileID=14947]
 +
 
 +
37. Meenach, S.A., Anderson, K.W., Hilt, J.Z., McGarry, R.C., and '''*Mansour, H.M.*''' ''Characterization and Aerosol Dispersion Performance of Advanced Spray-Dried Chemotherapeutic PEGylated Phospholipid Particles for Dry Powder Inhalation Delivery in Lung Cancer.'' [[European Journal of Pharmaceutical Sciences]] (2013) 49 (4): 699-711.(Impact Factor: 3.212)[http://www.sciencedirect.com/science/article/pii/S0928098713001917]
38. Wu,X., Hayes, D Jr., Zwischenberger, J.B., Kuhn, R.J., and '''*Mansour, H.M.*''' ''Design and Physicochemical Characterization of Advanced Spray-Dried Tacrolimus  Multifunctional Particles for Inhalation.'' [[Drug Design, Development, and Therapy]]  (2013) 7:59-72. (Impact Factor: 3.486) [http://www.dovepress.com/getfile.php?fileID=15100]
38. Wu,X., Hayes, D Jr., Zwischenberger, J.B., Kuhn, R.J., and '''*Mansour, H.M.*''' ''Design and Physicochemical Characterization of Advanced Spray-Dried Tacrolimus  Multifunctional Particles for Inhalation.'' [[Drug Design, Development, and Therapy]]  (2013) 7:59-72. (Impact Factor: 3.486) [http://www.dovepress.com/getfile.php?fileID=15100]
Line 252: Line 270:
39. Wu,X., Zhang, W., Hayes, D Jr., and '''*Mansour, H.M.*''' ''Physicochemical Characterization and Aerosol Dispersion Performance of Organic Solution Advanced Spray-Dried Cyclosporine A Multifunctional Particles for Dry Powder Inhalation Aerosol Delivery.'' [[International Journal of Nanomedicine]] (2013) 8 :1269-1283.(Impact Factor: 3.463)[http://www.dovepress.com/getfile.php?fileID=15566]
39. Wu,X., Zhang, W., Hayes, D Jr., and '''*Mansour, H.M.*''' ''Physicochemical Characterization and Aerosol Dispersion Performance of Organic Solution Advanced Spray-Dried Cyclosporine A Multifunctional Particles for Dry Powder Inhalation Aerosol Delivery.'' [[International Journal of Nanomedicine]] (2013) 8 :1269-1283.(Impact Factor: 3.463)[http://www.dovepress.com/getfile.php?fileID=15566]
-
40. Hayes, D. Jr., Galantowicz, M., Yates, A.R., Preston, T.J., '''Mansour, H.M.''', and McConnell, P.I. ''Venovenous ECMO as a Bridge to Lung Transplant and Protective Strategy for Subsequent Primary Graft Dysfunction.'' [[Journal of Artificial Organs]] (2013) 16 (3): 382-385. (Impact Factor: 1.60)[http://link.springer.com/article/10.1007%2Fs10047-013-0699-z]
+
40. Park, C.W., Li X., Vogt, F.G., Hayes, D. Jr., Zwischenberger, J.B., Park, E.S. and '''*Mansour, H.M.*''' ''Advanced Spray Dried Design, Physicochemical Characterization and Aerosol Dispersion Performance of Vancomycin and Clarithromycin Multifunctional Controlled Release Particles for Targeted Respiratory Delivery as Dry Powder Inhalation Aerosols..'' [[International Journal of Pharmaceutics]] (2013) 455 (1–2): 374–392.(Impact Factor: 3.458)[http://www.sciencedirect.com/science/article/pii/S0378517313005565]
-
41. Hayes, D. Jr., Baker, P.B., '''Mansour, H.M.''', Peeples, M.E., and Nicol, K.K. ''Interstitial Lung Disease in a Child with Antisynthetase Syndrome.'' [[Lung]] (2013) 191 (4): 441-443. (Impact Factor: 2.062)[http://link.springer.com/article/10.1007%2Fs00408-013-9468-2]
+
41. Zheng Z, Zhang W, Sun W, Li X, Duan J, Cui J, Feng Z, and '''*Mansour, H.M.*''' ''Influence of the Carboxymethyl Chitosan Anti-Adhesion Solution on the TGF-β1 in a Postoperative Peritoneal Adhesion Rat.'' [[Journal of Materials Science: Materials in Medicine]] (2013) 24 (11): 2549-2559. (Impact Factor: 2.141) [http://link.springer.com/article/10.1007/s10856-013-4981-7]
-
42.Hayes, D. Jr., Daniels, C.J., '''Mansour, H.M.''', Kopp, B.T., Yates, A.R., McCoy, K.S., Patel, A.V., and Kirby, S. ''Right Heart Catherization Measuring Central Hemodynamics in Cystic Fibrosis During Exercise.'' [[Respiratory Medicine]] (2013): 107 (9): 1365–1369. [Impact Factor: 2.475][http://www.sciencedirect.com/science/article/pii/S0954611113002096]
+
42. Duan J.H., Vogt, F.G., Li X., Hayes, D. Jr., and '''*Mansour, H.M.*''' ''Design, Physicochemical Characterization and Aerosolization of Organic Solution Advanced Spray Dried and Co-Spray Dried Moxifloxacin and Ofloxacin Dipalmitoylphosphatidylcholine (DPPC) Microparticulate/Nanoparticulate Powders for Pulmonary Inhalation Aerosol Delivery.'' [[International Journal of Nanomedicine]] (2013) 8: 3489-3505. [http://www.dovepress.com/getfile.php?fileID=17495](Impact Factor: 3.463)
-
43. Hayes, D. Jr., Daniels, C.J., '''Mansour, H.M.''', Kopp, B.T., Yates, A.R., Preston, T., and Kirby, S. ''Identification of the Nodose Ganglia and TRPV1 in Swine.'' [[Lung]] (2013): 191(5):445-447(Impact Factor: 2.062)[http://link.springer.com/content/pdf/10.1007%2Fs00408-013-9496-y.pdf]
+
43. Hayes, D. Jr., Galantowicz, M., Yates, A.R., Preston, T.J., '''Mansour, H.M.''', and McConnell, P.I. ''Venovenous ECMO as a Bridge to Lung Transplant and Protective Strategy for Subsequent Primary Graft Dysfunction.'' [[Journal of Artificial Organs]] (2013) 16 (3): 382-385. (Impact Factor: 1.414)[http://link.springer.com/article/10.1007%2Fs10047-013-0699-z]
-
44. Hayes, D. Jr., Yates, A.R., Duffy, V., Tobias, J., '''Mansour, H.M.''', Olshove, V., and Preston, T.J. ''Rapid placement of bicaval dual-lumen catheter in a swine model of venovenous ECMO.'' [[Journal of Investigative Surgery]] (2013): ''(''in press'')''  [Impact Factor: 1.316] [http://informahealthcare.com/doi/abs/10.3109/08941939.2013.826311]
+
44. Hayes, D. Jr., Baker, P.B., '''Mansour, H.M.''', Peeples, M.E., and Nicol, K.K. ''Interstitial Lung Disease in a Child with Antisynthetase Syndrome.'' [[Lung]] (2013) 191 (4): 441-443. (Impact Factor: 2.062)[http://link.springer.com/article/10.1007%2Fs00408-013-9468-2]
-
45. '''*Mansour, H.M.*''' and Hayes, D. Jr.''Inhalable Phospholipid and Lipopolymeric Self-Assemblies for Targeted Pulmonary Delivery as Aerosolized Colloidal Dispersions and Dry Powder Inhalers. Invited Paper.'' [[Pharmaceutics: Special Issue: Liposomal Technologies ]] (2013)[http://www.mdpi.com/journal/pharmaceutics/special_issues/liposome_technologies#planned]
+
45.Hayes, D. Jr., Daniels, C.J., '''Mansour, H.M.''', Kopp, B.T., Yates, A.R., McCoy, K.S., Patel, A.V., and Kirby, S. ''Right Heart Catherization Measuring Central Hemodynamics in Cystic Fibrosis During Exercise.'' [[Respiratory Medicine]] (2013): 107 (9): 1365–1369. [Impact Factor: 2.585][http://www.sciencedirect.com/science/article/pii/S0954611113002096]
-
46. Meenach, S.A., Anderson, K.W., Hilt, J.Z., McGarry, R.C., and '''*Mansour, H.M.*''' ''Characterization and Aerosol Dispersion Performance of Advanced Spray-Dried Chemotherapeutic PEGylated Phospholipid Particles for Dry Powder Inhalation Delivery in Lung Cancer.'' [[European Journal of Pharmaceutical Sciences]] (2013) 49 (4): 699-711.(Impact Factor: 3.212)[http://www.sciencedirect.com/science/article/pii/S0928098713001917]
+
46. Hayes, D. Jr., Daniels, C.J., '''Mansour, H.M.''', Kopp, B.T., Yates, A.R., Preston, T., and Kirby, S. ''Identification of the Nodose Ganglia and TRPV1 in Swine.'' [[Lung]] (2013): 191(5):445-447(Impact Factor: 2.062)[http://link.springer.com/content/pdf/10.1007%2Fs00408-013-9496-y.pdf]
-
47. Park, C.W., Li X., Vogt, F.G., Hayes, D. Jr., Zwischenberger, J.B., Park, E.S. and '''*Mansour, H.M.*''' ''Advanced Spray Dried Design, Physicochemical Characterization and Aerosol Dispersion Performance of Vancomycin and Clarithromycin Multifunctional Controlled Release Particles for Targeted Respiratory Delivery as Dry Powder Inhalation Aerosols..'' [[International Journal of Pharmaceutics]] (2013) 455 (1–2): 374–392.(Impact Factor: 3.458)[http://www.sciencedirect.com/science/article/pii/S0378517313005565]
+
47.Hayes, D Jr., Kirkby, S., McCoy, K.S., '''Mansour, H.M.''', Khosravi, M., Strawbridge, H., and Tobias, J.D.  ''Reduction of Lipid-Laden Macrophage Index After Laproscopic Nissen Fundoplication in Cystic Fibrosis Patients After Lung Transplantation.'' [[Clinical Transplantation]] (2013) 27 (1): 121-125.(Impact Factor: 1.634) [http://onlinelibrary.wiley.com/doi/10.1111/ctr.12020/abstract]
-
48. Zheng Z, Zhang W, Sun W, Li X, Duan J, Cui J, Feng Z, and '''*Mansour, H.M.*''' ''Influence of the Carboxymethyl Chitosan Anti-Adhesion Solution on the TGF-β1 in a Postoperative Peritoneal Adhesion Rat.'' [[Journal of Materials Science: Materials in Medicine]] (2013) 24 (11): 2549-2559. (Impact Factor: 2.141) [http://link.springer.com/article/10.1007/s10856-013-4981-7]
 
-
49. Duan J.H., Vogt, F.G., Li X., Hayes, D. Jr., and '''*Mansour, H.M.*''' ''Design, Physicochemical Characterization and Aerosolization of Organic Solution Advanced Spray Dried and Co-Spray Dried Moxifloxacin and Ofloxacin Dipalmitoylphosphatidylcholine (DPPC) Microparticulate/Nanoparticulate Powders for Pulmonary Inhalation Aerosol Delivery.'' [[International Journal of Nanomedicine]] (2013) 8: 3489-3505.  [http://www.dovepress.com/getfile.php?fileID=17495](Impact Factor: 3.463)
 
-
50. Li X., Vogt, F.G., Hayes, D. Jr., and '''*Mansour, H.M.*''' ''Design, Characterization and Aerosol Dispersion Performance Modeling of Organic Solution Advanced Spray Dried Microparticulate/Nanoparticulate Mannitol Powders for Targeted Pulmonary Delivery as Dry Powder Inhalation Aerosols.'' [[Journal of Aerosol Medicine & Pulmonary Drug Delivery: 2013 ISAM World Congress Special Issue]] (2013) (Impact Factor: 3)
+
'''== 2014 =='''
-
51. Li X., Vogt, F.G., Hayes, D. Jr., and '''*Mansour, H.M.*''' ''Physicochemical Characterization and Aerosol Dispersion Performance of Organic Solution Advanced Spray Dried Microparticulate/Nanoparticulate Antibiotic Dry Powders of Tobramycin and Azithromycin for Pulmonary Inhalation Aerosol Delivery.'' [[European Journal of Pharmaceutical Sciences]] (2013) (Impact Factor: 2.987)''(IN PRESS)'' [http://www.sciencedirect.com/science/article/pii/S0928098713004235]
+
48. Hayes, D. Jr., Yates, A.R., Duffy, V., Tobias, J., '''Mansour, H.M.''', Olshove, V., and Preston, T.J. ''Rapid placement of bicaval dual-lumen catheter in a swine model of venovenous ECMO.'' [[Journal of Investigative Surgery]] (2014): 27(1):27-31. [Impact Factor: 1.316] [http://informahealthcare.com/doi/abs/10.3109/08941939.2013.826311]
-
52. Hayes, D. Jr., Adler, B., Duffy, V., Turner, T.L., and '''Mansour, H.M.'''. ''Alternative Tacrolimus and Sirolimus Regimen Associated with Rapid Resolution of Posterior Reversible Encephalopathy Syndrome After Lung Transplantation.''  [[Pediatric Neurology]] (2013) (Impact Factor: 1.416)''(IN PRESS)'' [http://www.sciencedirect.com/science/article/pii/S0887899413006693]
+
49. Hayes, D. Jr., Adler, B., Turner, T.L., and '''Mansour, H.M.'''. ''Alternative Tacrolimus and Sirolimus Regimen Associated with Rapid Resolution of Posterior Reversible Encephalopathy Syndrome After Lung Transplantation.''  [[Pediatric Neurology]] (2014) 50: 272-275.(Impact Factor: 1.416)[http://www.sciencedirect.com/science/article/pii/S0887899413006693]
 +
 
 +
50. Hayes, D. Jr., Adler, B., Duffy, V., Turner, T.L., and '''Mansour, H.M.'''. ''Precordial Catch Syndrome in Elite Swimmers with Asthma.''[[Pediatric Emergency Care]] (2014)
 +
 
 +
51. Li X., Vogt, F.G., Hayes, D. Jr., and '''*Mansour, H.M.*''' ''Physicochemical Characterization and Aerosol Dispersion Performance of Organic Solution Advanced Spray Dried Microparticulate/Nanoparticulate Antibiotic Dry Powders of Tobramycin and Azithromycin for Pulmonary Inhalation Aerosol Delivery.'' [[European Journal of Pharmaceutical Sciences]] (2014) 15: 191-205. (Impact Factor: 2.987) [http://elsarticle.com/1ej23qD]
 +
 
 +
52. Li X., Vogt, F.G., Hayes, D. Jr., and '''*Mansour, H.M.*''' ''Design, Characterization, and Aerosol Dispersion Performance Modeling of Advanced Spray-Dried Microparticulate/Nanoparticulate Mannitol Powders for Targeted Pulmonary Delivery as Dry Powder Inhalers.'' [[Journal of Aerosol Medicine & Pulmonary Drug Delivery: 2013 ISAM World Congress Special Issue]] (2014): 27 (2):1-13. (Impact Factor: 2.894)[http://online.liebertpub.com/doi/pdfplus/10.1089/jamp.2013.1078]
 +
 
 +
53. Muralidharan, P., Mallory, E., Malapit, M., Hayes, D. Jr., and '''*Mansour, H.M.*''' ''Inhalable PEGylated Phospholipid Nanocarriers and PEGylated Therapeutics for Respiratory Delivery as Aerosolized Colloidal Dispersions and Dry Powder Inhalers. Invited Paper.'' [[Pharmaceutics: Special Issue: Liposomal Technologies ]] (2014)[http://www.mdpi.com/journal/pharmaceutics/special_issues/liposome_technologies#planned]
 +
 
 +
54. Muralidharan, P., Malapit, M., Mallory, E., Hayes, D. Jr., and '''*Mansour, H.M.*''' ''Inhalable Nanoparticulate Powders for Respiratory Delivery. Invited Paper.'' [[Nanomedicine]] (2014)(Impact Factor: 5.26)[http://www.futuremedicine.com/loi/nnm]
==Edited Book (co-Editor)==
==Edited Book (co-Editor)==
Line 290: Line 316:
4. '''*Mansour, H.M.*''', Park, C.W., and Hayes, D. Jr. ''Book Chapter 3: Nanoparticle Lung Delivery and Inhalation Aerosols for Targeted Pulmonary Nanomedicine.'' [[Nanomedicine in Drug Delivery.]] Kumar, A., '''Mansour, H.M.''', Friedman, A., Blough, E. (Editors), First Edition, CRC Press/Taylor & Francis, Inc., London, United Kingdom.  (2013): pp.43-74. [http://www.crcpress.com/product/isbn/9781466506169] [http://books.google.com/books?hl=en&lr=&id=QWhSMfsn6tYC&oi=fnd&pg=PP1&dq=info:Lf0jl2sCR2EJ:scholar.google.com&ots=wxUAiFY--3&sig=tX2bBhGxBV0twoAczpmjuezUt2U#v=onepage&q&f=false][http://www.taylorandfrancis.com/books/details/9781466506169/]
4. '''*Mansour, H.M.*''', Park, C.W., and Hayes, D. Jr. ''Book Chapter 3: Nanoparticle Lung Delivery and Inhalation Aerosols for Targeted Pulmonary Nanomedicine.'' [[Nanomedicine in Drug Delivery.]] Kumar, A., '''Mansour, H.M.''', Friedman, A., Blough, E. (Editors), First Edition, CRC Press/Taylor & Francis, Inc., London, United Kingdom.  (2013): pp.43-74. [http://www.crcpress.com/product/isbn/9781466506169] [http://books.google.com/books?hl=en&lr=&id=QWhSMfsn6tYC&oi=fnd&pg=PP1&dq=info:Lf0jl2sCR2EJ:scholar.google.com&ots=wxUAiFY--3&sig=tX2bBhGxBV0twoAczpmjuezUt2U#v=onepage&q&f=false][http://www.taylorandfrancis.com/books/details/9781466506169/]
-
5. '''*Mansour, H.M.*''', Park, C.W., and Bawa, R. ''Book Chapter 6: Design and Development of Approved Nanopharmaceutical Products.'' [[Handbook of Clinical Nanomedicine: From Bench to Bedside]]. Bawa, R., Audette, G., and Rubinstein, I. (Editors),Pan Stanford Publishing/Taylor & Francis, Boca Raton, FL, (2013): pp. 1-27. [http://www.crcpress.com/product/isbn/9789814316170]
+
5. '''*Mansour, H.M.*''', Park, C.W., and Bawa, R. ''Book Chapter 6: Design and Development of Approved Nanopharmaceutical Products.'' [[Handbook of Clinical Nanomedicine: From Bench to Bedside]]. Bawa, R., Audette, G., and Rubinstein, I. (Editors),Pan Stanford Publishing/Taylor & Francis, Boca Raton, FL, (2014): pp. 1-27. [http://www.crcpress.com/product/isbn/9789814316170]
-
6. '''*Mansour, H.M.*''', Xu, Z., Meenach, S.A., Park, C.W., Rhee, Y.S., and DeLuca, P.P. ''Book Chapter 4: Novel Drug Delivery Systems.'' [[Drug Delivery.]] Mitra, A.K. (Editor), First Edition,  Jones & Bartlett, Burlington, MA. (2013).
+
6. '''*Mansour, H.M.*''', Xu, Z., Meenach, S.A., Park, C.W., Rhee, Y.S., and DeLuca, P.P. ''Book Chapter 4: Novel Drug Delivery Systems.'' [[Drug Delivery.]] Mitra, A.K. (Editor), First Edition,  Jones & Bartlett, Burlington, MA. (2014)''IN PRESS''.
-
7.'''*Mansour, H.M.*''', Meenach, S.A., and Hayes, D. Jr. ''Book Chapter 12: Pulmonary Drug Delivery.'' [[Drug  Delivery & Targeting.]] Hillery, A.M., Swarbrick, J., and Park, K., (Editors), Second Edition,  CRC Press/Taylor & Francis, Inc.,  London, United Kingdom. (2013).
+
7.'''*Mansour, H.M.*''', Myrdal, P.B., Younis, U., and Hayes, D. Jr. ''Book Chapter 12: Pulmonary Drug Delivery.'' [[Drug  Delivery & Targeting.]] Hillery, A.M., Swarbrick, J., and Park, K., (Editors), Second Edition,  CRC Press/Taylor & Francis, Inc.,  London, United Kingdom. (2014).
== Professional Memberships==
== Professional Memberships==
Line 333: Line 359:
Current Position: Assistant Professor, Gyeongsang National University, S. Korea.[http://www.ddscenter.com/intro/int_03_7.html]
Current Position: Assistant Professor, Gyeongsang National University, S. Korea.[http://www.ddscenter.com/intro/int_03_7.html]
-
2. Dr. Xiao Wu, Ph.D.(University of Bath College of Pharmacy, Bath, England. Ph.D. Advisor: Dr. Richard Guy), Postdoctoral Research Scholar.  
+
2. Dr. Xiao Wu, Ph.D.(University of Bath College of Pharmacy, Bath, England. Ph.D. Advisor: Dr. Richard Guy), Postdoctoral Research Scholar. Current Position: Formulation Chemist, Eli Lilly Animal Health Division (Elanco), Indianapolis, IN.
-
Current Position: University of Michigan-Ann Arbor.
+
3. Dr. Chun-Woong Park, Ph.D.(SungKyunKwan University College of Pharmacy, S. Korea. Ph.D. Advisor: Dr. Eun-Seok Park), Postdoctoral Research Scholar.  
3. Dr. Chun-Woong Park, Ph.D.(SungKyunKwan University College of Pharmacy, S. Korea. Ph.D. Advisor: Dr. Eun-Seok Park), Postdoctoral Research Scholar.  
Line 358: Line 383:
11. Dr. Lauren Willis, Pharm.D. Researcher. Current Position: Clinical Faculty at MD Anderson Cancer Center
11. Dr. Lauren Willis, Pharm.D. Researcher. Current Position: Clinical Faculty at MD Anderson Cancer Center
-
12. Priya Muralidharan, M.S.(New Jersey Institute of Technology-Pharmaceutical Engineering), Predoctoral Candidate & Lab Manager.
+
12. Priya Muralidharan, M.S.(New Jersey Institute of Technology-Pharmaceutical Engineering), Predoctoral Graduate Student & Lab Manager.
 +
 
 +
13. Monica Malapit, Pharm.D. Graduate Researcher.
-
13. Monica Malapit, Pharm.D. Researcher.
+
14. Evan Mallory, Pharm.D. Graduate Researcher.
==Co-Advisor Lab Group Members==
==Co-Advisor Lab Group Members==
Line 366: Line 393:
1. Nathanael Stocke, NSF-IGERT Fellow & NIH NCI CNTC Fellow, College of Engineering[http://www.cntc.uky.edu/research-areas/magnetic-nanocomposites-microparticles-mnms-for-lung-cancer-treatment-via-targeted-pulmonary-delivery/] [http://www.cntc.uky.edu/trainees/] [http://igert.engr.uky.edu/students/]
1. Nathanael Stocke, NSF-IGERT Fellow & NIH NCI CNTC Fellow, College of Engineering[http://www.cntc.uky.edu/research-areas/magnetic-nanocomposites-microparticles-mnms-for-lung-cancer-treatment-via-targeted-pulmonary-delivery/] [http://www.cntc.uky.edu/trainees/] [http://igert.engr.uky.edu/students/]
-
2. Alexander McKinlay, NSF-REU Fellow, Department of Biomedical Engineering[http://mcdevitt.gatech.edu/profile/alex-k-mckinlay-iii]
+
2. Alexander McKinlay, NSF-REU Fellow, Department of Biomedical Engineering[http://mcdevitt.gatech.edu/profile/alex-mckinlay]
== Meeting Abstracts selected from 2006-Present (over 30 abstracts prior to 2006)*Presenting Author* ==
== Meeting Abstracts selected from 2006-Present (over 30 abstracts prior to 2006)*Presenting Author* ==

Revision as of 15:52, 14 February 2014


"The Leading Research University in the American Southwest"

Contents

Contact Info at "The Leading Research University in the American Southwest"

The University of Arizona-Tucson

College of Pharmacy

1703 E. Mabel St.

Office 434/Lab 435 Skaggs Pharmaceutical Sciences Center

Tucson, AZ 85721-0202.

Email: mansour@pharmacy.arizona.edu

Office Telephone: (520) 626-2768

Lab Telephone:(520) 626-3232

Fax: (520) 626-7355

Websites

Research & Education: [1] Graduate Program-Faculty Member:[2] Institute of the Environment-Affiliated Faculty Member: [3] NCI Comprehensive Cancer Center[4]-Associate Member: [5]

Google Scholar Publications: [6] PubMed Publications: [7] LinkedIn Profile: [8] Research Gate Profile: [9]

College of Pharmacy: http://www.pharmacy.arizona.edu

http://www.pharmacy.arizona.edu/visitors/college-of-pharmacy-facts

The University of Arizona: http://www.arizona.edu/about/highlights-rankings

http://uanews.org/story/ua-ranked-among-top-100-universities-in-world

http://uanews.org/story/ua-maintains-its-top-global-university-status

The University of Arizona Medical Center: http://uanews.org/story/university-of-arizona-medical-center-again-a-u-s-news-best-hospital

http://uanews.org/story/more-than-100-ua-physicians-among-best-doctors-in-america

Professor Mansour Links

1. University of Wisconsin-Madison: [10] [11]

2. Tel Aviv University: [12] [13]

3. Harvard Medical School: [14]

4. Standford University School of Medicine: [15]

5. Emory University School of Medicine: [16]

6. University of Texas Southwestern Medical Center: [17]

7. Case Western Reserve University: [18]

8. University of Colorado-Denver:[19][20]

9.University of Utah: [21]

Education

Postdoctorate, University of North Carolina-Chapel Hill[22], School of Pharmacy[23], 1/2006-6/2008

Postdoctorate, University of Wisconsin-Madison[24], School of Pharmacy[25][26], 2004

Ph.D. Major-Pharmaceutical Sciences (Pharmaceutics & Drug Delivery), University of Wisconsin-Madison, School of Pharmacy, 12/2003

Ph.D. Minor-Advanced Physical & Biophysical Interfacial Chemistry, University of Wisconsin-Madison, Department of Chemistry, 12/1999

B.S.-Pharmacy (Distinction & Honors), University of Wisconsin-Madison, 5/1996

Research Program

Research in the Mansour lab focuses on the fundamental and applied aspects of surface and interfacial chemistry, nanotechnology, and particle engineering technologies in the design and optimization of advanced drug delivery systems. Multifunctional polymeric phospholipid (lipopolymeric) self-assemblies are optimized for targeted drug delivery, nanomedicine, and multifunctional microparticles and nanoparticles in the solid-state as dry powder inhalation aerosols in the targeted treatment and prevention of several pulmonary diseases. These microparticulate/nanoparticulate dry powders which are targeted directly to the lung as dry powder inhalers are biocompatible, biodegradable, mucopenetrating, and provide sustained drug release. We utilize various types of inhaler devices for both in vitro and in vivo rodent animal models. A systematic Quality-by-Design (QbD) approach in the solid-state is used and includes comprehensive physicochemical characterization, design of experiments (DOEs), performance modeling, and prediction. Pulmonary diseases with unmet medical needs that we investigate in vitro and in vivo include lung transplantation, lung cancer, infectious diseases, lung inflammatory fibrotic diseases, and autoimmune diseases. Our research program includes translational medicine, as exemplified by several successful collaborations with physician-scientists.

Editorial Advisory Board Member (EAB)& Scientific Advisor

1. Pharmaceutical Technology North America[27]

2. Recent Patents on Nanomedicine [28]

3. Recent Patents on Drug Delivery & Formulation [29]

4. Journal of Pharmaceutical Technology & Drug Research (United Kingdom) [30]

5. Journal of Pharmaceutical Sciences-Scientific Advisor to the Editors [31]

National Expert Committees

1. NIH/NICHD U.S. Pediatric Formulations Initiative (PFI) New Drug Delivery Systems (NDDS) Working Group-Aerosols

Honors & Awards

  • 2010, Mercer School of Pharmacy Dept of Pharmaceutical Sciences, Pharmabeat 2010 Researcher of the Issue, Mercer University
  • 2007, NIH Regional Training Award Scholar, National Institutes of Health (NIH)/UNC-Chapel Hill
  • 2007-2008, Post Doctoral Fellow Award in Pharmaceutics, PhRMA Foundation
  • 2007-2008, Post Doctoral Scholars Award for Research Excellence, Office of the Vice Chancellor, University of North Carolina at Chapel Hill
  • 2007, Post Doctoral Fellow Award in Research Excellence, American Association of Pharmaceutical Scientists (AAPS)
  • 2001, Walter F. Enz Award in Research Excellence in the Pharmaceutical Sciences, Pharmacia Upjohn Global Pharmaceutical Sciences
  • 2000-2002, PhRMA Advanced Predoctoral Fellow Award in Pharmaceutics, Pharmaceutical Researchers & Manufacturers of America (PhRMA) Foundation
  • 1999-2001, AFPE Predoctoral Fellow Award, American Foundation for Pharmaceutical Education (AFPE)
  • 1996, Merck Award in Excellence in Pharmacy, Merck
  • 1996, Distinction and Honors in Pharmacy, School of Pharmacy, University of Wisconsin-Madison
  • 1994, Academic Excellence Award, Rho Chi Pharmaceutical Honor Society
  • 1993, Sophomore Honors Award, College of Letters and Science, University of Wisconsin-Madison
  • 1992, Chemistry Enrichment Award, Department of Chemistry, University of Wisconsin-Madison
  • 1991-1995, Wisconsin Academic Excellence Award Scholar, Wisconsin Governor & Wisconsin State Legislature
  • 1991, US Presidential Academic Fitness Award Scholar, President of the United States & the United States of America Congress
  • 1991, Elected Member, Phi Eta Sigma National Honor Society
  • 1991, Elected Member, Phi Kappa Phi National Honor Society
  • 1991, Elected Member, Golden Key International Honor Society

Invited Speaker (2005-Present)

National and International Invited Speaker Presentations

1.Yale University, Department of Biomedical Engineering, New Haven, CT. 2005.

2.Harvard University, Division of Engineering and Applied Sciences, Cambridge, MA. 2005.

3.UNC-Chapel Hill, Chapel Hill, NC. 2005.

4.10th Annual Liposome Research Days & 1st UNC Drug Conference, Chapel Hill, NC. 2006.

5.American Oil Chemist's Society (AOCS) Annual Meeting & Exhibition, Phoenix, AZ. Symposium on Phospholipids:"Lipids in Nanotechnology II". Invited Speaker. Presentation Title: “Designed Phospholipid Self-Assemblies in Drug Delivery and Nanomedicine”. 2010. [32]

6.American Oil Chemist's Society (AOCS) Annual Meeting & Exhibition, Cincinnati, OH. Symposium on “Phospholipids in Pharma and Cosmetics Applications”. Invited Speaker. Presentation Title: "Phospholipid Nanopharmaceuticals in Advanced Drug Delivery". 2011. [33]

7.International Workshop on Physical Characterization of Pharmaceutical Solids (IWPCPS-13). Indianapolis, IN. Symposium on “Solid-State Transformation During Formulations and Processing”. Invited Speaker. Presentation Title: "Water Vapor-Solid Interactions and Effects on Solid-State Phase Transitions in Engineered Microparticulate/Nanoparticulate Pharmaceutical Powders". 2011.

8. International Workshop on Physical Characterization of Pharmaceutical Solids (IWPCPS-13). Indianapolis, IN. Symposium on “Imaging of Drugs and Dosage Forms to Better Understand Dissolution”. Invited Speaker. Presentation Title: "Imaging Techniques for Designed Microparticulate/Nanoparticulate Pharmaceutical Powders". 2011.

9. American Chemical Society (ACS) 242nd Annual Meeting & Exhibition, Division of Colloid & Surface Chemistry-Symposium on “Nanomedicine: Colloids & Surface Science”. Denver, CO. Symposium Session Chair Presider & Invited Symposium Speaker. Presentation Title: "Rational Design, Development, and Optimization of Nanopharmaceuticals for Targeted Drug Delivery in Nanomedicine: An Interfacial and Colloidal Science Approach”. 2011.

10. 4th Annual AAPS Nanotechnology & Nanomedicine Symposium, Louisville, KY. Invited Speaker. Presentation Title: "Advanced Spray-Dried Vancomycin Hydrochloride and Clarithromycin Lipospheres for Targeted Pulmonary Inhalation Aerosol Delivery." 2011.

11. Pfizer, Inc., Worldwide Research & Development, Global Headquarters, Groton, CT. Invited Speaker. Presentation Title: "Engineering Particles by Advanced Spray Drying for Drug Delivery." 2011.

12. Center for Pulmonary Research, Children's Hospital Research Institute, The Ohio State University, Columbus, OH. Invited Speaker in the Translational Pulmonary Research Seminar Series. Presentation Title: "Advances in Targeted Lung Nanomedicine as Inhalable Multifunctional Microparticles & Nanoparticles for Pulmonary Disease Treatment and Prevention." 2012.

13. International Conference & Exhibition on Nanotechnology & Nanomedicine. Omaha, NE. Invited Speaker. Presentation Title: "Advances in Targeted Lung Nanomedicine as Inhalable Multifunctional Microparticles & Nanoparticles for Pulmonary Disease Treatment and Prevention." 2012.

14.Transcept Pharmaceuticals. Invited Webinar Speaker. Presentation Title: "Fundamental and Applied Aspects of Sustained Release Injectible Depot Delivery". 2012.

15. Buchi Annual Spray Drying Short-Course, Buchi U.S. Headquarters. New Castle, DE. Invited Speaker/Short-Course Instructor. Presentation Title: "Engineering Particles by Advanced Organic Solution Spray Drying for Nanopharmaceuticals and Targeted Pulmonary Inhalation Aerosol Delivery." 2012. [34]

16. Lovelace Respiratory Research Institute (LRRI). Albuquerque, NM. Invited Speaker in the LRRI and CNTC Seminar Series. Presentation Title:"Advances in Targeted Lung Nanomedicine as Aerosolized Multifunctional Microparticles and Nanoparticles for Pulmonary Disease Treatment and Prevention." 2012. [35]

17. Controlled Release Society (CRS) 39th Annual Meeting & Exhibition. Quebec City, Quebec, Canada. Invited Speaker. CRS Workshop: "Mucosal Drug and Gene Delivery: Barriers and Opportunities." Presentation Title: "Pulmonary Drug Delivery". 2012.[36]

18. 1st International Symposium on Nanomedicine in Drug Delivery and Cancer Diagnosis. University of Delaware, College of Health Sciences, Newark, DE. Organizing Committee Member [37]. Nano Drug Delivery Session Chair Presider [38]. Invited Symposium Speaker in the Nanomedicine Session. Presentation Title: "Advances in Targeted Lung Nanomedicine as Multifunctional Microparticles & Nanoparticles for Targeted Pulmonary Delivery." 2012. [39]

19. Wayne State University Applebaum College of Pharmacy, Department of Pharmaceutical Sciences Seminar Series. Detroit, MI. Invited Speaker. 2012.[40]

20. North American Cystic Fibrosis Conference (NACFC), Orlando, FL. Invited Symposium Speaker. NACFC Aerosol Symposium: "Aerosol Treatments in CF: Clearing the Fog." Presentation Title: "Aerosol Formulation Issues." 2012.[41]

21. 19th World Congress of the International Society of Aerosols in Medicine (ISAM), Chapel Hill, NC. Invited Speaker. ISAM Workshop: "Nanomedicine & Nanotoxicology: Inhaling nanoparticles by accident and on purpose-challenges and opportunities for toxicology and therapeutics." Presentation Title: "Nanotechnology in Dry Powder Inhalation Aerosol Formulations." 2013.[42]

22. AAPS/USP/FDA/IPAC Workshop on Inhaled Drug Products, United States Pharmacopeia (USP), Rockville, MD. Invited Speaker. "Inhaled Drug Products: Current Practices and the Future of In Vitro Testing Technologies and Regulation." Presentation Title: "Solid-State Characterization and Nanotechnology in Inhalation Aerosol Formulation Development." 2013. [43]

23. Association of Inhalation Toxicologists (AIT) Annual Conference, Hannover, Germany. Invited Speaker. Session: "Nanomaterials." Presentation Title: "Nanomaterials as an Aerosol Formulation Carrier in Inhalation Aerosol Nanomedicine." 2013. [44]

24. Eastern Analytical Symposium & Exhibition (EAS), Somerset, NJ. Invited Speaker. Coblentz EAS Session: "Spectroscopic Applications in Biologics." Presentation Title:"Characterization and Spectroscopic Applications in Pulmonary Delivery and Advanced Dry Powder Inhalers." 2013. [45] [46]

Short-Course/Workshop Instructor

1.Aerosol School 2-Day Workshop: "Aerosol Science Fundamentals and Inhalation Aerosol Delivery", NIH-NCI Cancer Nanotechnology Training Center (CNTC), April 17-18 2012.

Journal Publications *Corresponding Author*

== 2001-2009 ==

1. Mansour H., Wang D.-S., Chen C.-S., and Zografi G. Comparison of Bilayer and Monolayer Properties of Phospholipid Systems Containing Dipalmitoylphosphatidylglycerol and Dipalmitoylphosphatidylinositol. Langmuir (2001) 17 (21) October 16: 6622-6632. (Impact Factor: 4.187)[47]

2. *Mansour, H.M.* and Zografi G. The Relationship Between Water Vapor Absorption and Desorption by Phospholipids and Bilayer Phase Transitions. Journal of Pharmaceutical Sciences (2007) 96 (2) February: 377-396. (Impact Factor: 3.13)[48]

3. *Mansour, H.M.* and Zografi G. Relationships Between Equilibrium Spreading Pressure and Phase Equilibria of Phospholipid Bilayers and Monolayers at the Air-Water Interface. Langmuir (2007) 23 (7) March 27: 3809-3819. (Impact Factor: 4.187)[49]

4. Hickey, A.J., Mansour, H.M., et al. Physical Characterization of Component Particles Included in Dry Powder Inhalers: I. Strategy Review and Static Characteristics. Journal of Pharmaceutical Sciences: Special Issue David Grant Dedicated Issue (2007) 96 (5) May: 1282-1301. (Impact Factor: 3.13)[50]

5. Hickey, A.J., Mansour, H.M., et al. Physical Characterization of Component Particles Included in Dry Powder Inhalers: II. Dynamic Characteristics. Journal of Pharmaceutical Sciences: Special Issue David Grant Dedicated Issue (2007) 96 (5) May: 1302-1319. (Impact Factor: 3.13)[51]

6. *Mansour, H.M.* and Hickey, A.J. Raman Characterization and Chemical Imaging of Biocolloidal Self-Assemblies, Drug Delivery Systems, and Pulmonary Inhalation Aerosols. A Review. AAPS PharmSciTech (2007) 8 (4) November 30: Article 99:E1-E16. (Impact Factor: 1.584)[52]

7. Xu, Z., Mansour, H.M., Mulder, T., McLean, R., Langridge, J., and Hickey, A.J. Comparative Dispersion Study of Dry Powder Aerosols of Albuterol Sulfate/Lactose Monohydrate and Cromolyn Sodium/Lactose Monohydrate Delivered by Standardized Entrainment Tubes. Respiratory Drug Delivery (2008) 3: 897-900. [53]

8. *Mansour H.M.*, Damodaran S., and Zografi G. Characterization of the In Situ Structural and Interfacial Properties of the Cationic Hydrophobic Heteropolypeptide, KL4, in Lung Surfactant Bilayer and Monolayer Models at the Air-Water Interface: Implications for Pulmonary Surfactant Delivery. Molecular Pharmaceutics (2008) 5 (5) October 6: 681-695. (Impact Factor: 4.57)[54]

9. *Mansour, H.M.*, Rhee, Y.S., and Wu, X. Nanomedicine in Pulmonary Delivery. International Journal of Nanomedicine (2009) 4 December: 299-319.(Impact Factor: 3.463)[55]


== 2010 ==

10. Xu, Z., Mansour, H.M., Mulder, T., McLean, R., Langridge, J., and Hickey, A.J. Dry Powder Aerosols Generated by Standardized Entrainment Tubes from Drug Blends with Lactose Monohydrate: 1. Albuterol Sulfate and Disodium Cromoglycate. Journal of Pharmaceutical Sciences (2010) 99 (8) March 2: 3398-3414.(Impact Factor: 3.13)[56]

11. Xu, Z., Mansour, H.M., Mulder, T., McLean, R., Langridge, J., and Hickey, A.J. Dry Powder Aerosols Generated by Standardized Entrainment Tubes from Drug Blends with Lactose Monohydrate: 2. Ipratropium Bromide Monohydrate and Fluticasone Propionate. Journal of Pharmaceutical Sciences (2010) 99 (8) March 10: 3415-3429. (Impact Factor: 3.13)[57]

12. Mansour, H.M., Xu, Z., and Hickey, A.J. Dry Powder Aerosols Generated by Standardized Entrainment Tubes from Alternative Sugar Blends: 3. Trehalose Dihydrate and D-Mannitol Carriers. Journal of Pharmaceutical Sciences (2010) 99 (8) March12; 3430-3441.(Impact Factor: 3.13)[58]

13. Xu, Z., Mansour, H.M., Mulder, T., McLean, R., Langridge, J., and Hickey, A.J. Heterogenous Particle Deaggregation and Its Implications for Therapeutic Aerosol Performance. Journal of Pharmaceutical Sciences (2010) 99 (8) March 15: 3442-3461.(Impact Factor: 3.13)[59]

14. *Mansour, H.M.*, Sohn, M., Al-Ghananeem, A., and DeLuca P.P. Materials for Pharmaceutical Dosage Forms: Molecular Pharmaceutics and Controlled Release Drug Delivery Aspects. Invited Paper. International Journal of Molecular Sciences: Special Issue-Material Sciences and Nanotechnology Section - Biodegradability of Materials in Biomedical Applications. (2010) 11: 3298-3322. (Impact Factor: 2.464)[60]

15. Rhee, Y.S., Park, C.W., DeLuca, P.P., and *Mansour, H.M.* Sustained-Release Injectable Drug Delivery Systems. An Invited Paper. Pharmaceutical Technology: Special Issue-Drug Delivery (2010) November: 6-13. [61]

16. Hayes, D. Jr., Zwischenberger, J.B., and Mansour, H.M. Aerosolized Tacrolimus: A Case Report in a Lung Transplant Recipient. Transplantation Proceedings (2010) 42 (9) November: 3876-3879. [62]

17. Wu, X., Li, X., and *Mansour, H.M.* Surface Analytical Techniques in Solid-State Particle Characterization: Implications for Predicting Performance in Dry Powder Inhalers. Invited Paper. KONA Powder and Particle Journal (2010) 28: 3-19. [63]


== 2011 ==

18. Xu, Z., Mansour, H.M., and Hickey, A.J. Particle Interactions in Dry Powder Inhaler Unit Processes. Journal of Adhesion Science and Technology: Special Issue on Adhesion Aspects in Pharmaceutical Sciences (2011): 25 (4/5) 451-482. (Impact Factor: 1.175)[64]

19. Rhee, Y.S. and *Mansour, H.M.* Nanopharmaceuticals I: Nanocarrier Systems in Drug Delivery. Invited Paper. International Journal of Nanotechnology: Special Issue-Nanopharmaceuticals. (2011) 8 (1/2): 84-114.[65]

20. Wu, X. and *Mansour, H.M.* Nanopharmaceuticals II: Application of Nanoparticles and Nanocarrier Systems in Pharmaceutics and Nanomedicine. Invited Paper. International Journal of Nanotechnology: Special Issue-Nanopharmaceuticals. (2011) 8 (1/2): 115-145. (Impact Factor: 1.329)[66]

21. Wu, X.,and *Mansour, H.M.* Pulmonary and Nasal Anti-Inflammatory and Anti-Allergy Inhalation Aerosol Delivery Systems. Invited Paper. Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry: Special Issue-Optimizing a Therapeutic with Anti-Inflammatory Agents: Novel Drug Delivery Systems. (2011)10 (3): 215-229. [67]

22. Park, C.W., Hayes, D. Jr., and *Mansour, H.M.* Pulmonary Inhalation Aerosols for Targeted Antibiotics Drug Delivery. Invited Paper & Cover Page. European Pharmaceutical Review. (2011) 16 (1): 32-36.[68]

23. *Mansour, H.M.* Molecular Forces and Self Assembly in Colloid, Nano Sciences and Biology. Invited Paper. Journal of the American Chemical Society. (2011) 133 (13): 5162. (Impact Factor: 9.907) [69]

24. Hayes, D. Jr and Mansour, H.M. Improved Outcomes of Patients with End-Stage Cystic Fibrosis Requiring Invasive Mechanical Ventilation for Acute Respiratory Failure. Lung. (2011) 189 (5): 409-415. (Impact Factor: 2.062)[70] [71]

25. Hayes, D. Jr., Ball, A.M., Mansour, H.M., Martin, C.A.,and Flynn, J.D. Fungal Infection in Heart-Lung Transplant Recipients Receiving Single-agent Prophylaxis With Itraconazole. Experimental and Clinical Transplantation (2011)9 (6): 399-404. [72].

26. Rhee, Y.S., Sohn, M., Woo, B.H., Thanoo, B.C., DeLuca, P.P., and *Mansour, H.M.* Sustained-Release Delivery of Octreotide from Biodegradable Polymeric Microspheres. AAPS PharmSciTech: Special Theme Issue-Sterile Products: Advances and Challenges in Formulation, Manufacturing, Devices and Regulatory Aspects.(2011)12 (4):1293-1301. (Impact Factor: 1.584)[73] [74]

27. Li, X. and *Mansour, H.M.* Physicochemical Characterization and Water Vapor Absorption of Organic Solution Advanced Spray Dried Trehalose Microparticles and Nanoparticles for Targeted Dry Powder Pulmonary Inhalation Delivery. AAPS PharmSciTech: Special Theme Issue: Advances in Pharmaceutical Excipients Research and Use: Novel Materials, Functionalities and Testing (2011)12(4):1420-1430. (Impact Factor: 1.584)[75] [76]


== 2012 ==

28. Hayes, D. Jr., Winkler, M.A., Kirkby, S., Capasso, P., Mansour, H.M. and Attili, A.K. Preprocedural Planning with Prospectively Triggered Multi-Detector Row CT Angiography prior to Bronchial Artery Embolization in Cystic Fibrosis Patients with Massive Hemoptysis. Lung (2012)190 (2)April:221-225.(Impact Factor: 2.062)[77]

29. Hayes, D. Jr. and Mansour, H.M. Vanishing Bronchus Intermedius Syndrome in a Pediatric Patient with Cystic Fibrosis After Lung Transplantation. Pediatric Transplantation: The Official Journal of the International Pediatric Transplant Association (2012)16(8):333-337. [Impact Factor: 1.5][78]

30. Hayes, D. Jr., Mansour, H.M., Kirkby, S., and Phillips, A.B. Rapid Acute Onset of Bronchiolitis Obliterans Syndrome in a Lung Transplant Recipient After Respiratory Syncytial Virus Infection." Transplant Infectious Diseases (2012)14 (5): 548-550. [Impact Factor: 2.216][79]

31. Duan, J.H., Mansour, H.M., Zhang, Y.D., Deng, X.M., Zhao, J.F. Reversion of Multi-Drug Resistance by Co-Encapsulation of Doxorubicin and Curcumin in Chitosan/poly(butylcyanoacrylate) Nanoparticles. International Journal of Pharmaceutics (2012) 426 (1-2): 193-201. (Impact Factor: 3.458)[80]

32. Park, C.W., Mansour, H.M., Oh, T.O., Kim, J.Y., Ha, J.M., Lee, B.J., Chi, S.C., Rhee, Y.S., Park, E,S. "Phase behavior of itraconazole-phenol mixtures and its pharmaceutical applications." International Journal of Pharmaceutics (2012) 436 (1-2):652-658.(Impact Factor: 3.458) [81]

33. Park, C.W., Rhee, Y.S., Vogt, F.G., Hayes, D Jr., Zwischenberger, J.B., DeLuca, P.P., and *Mansour, H.M.* Advances in Microscopy and Complementary Imaging Techniques to Assess the Fate of Drugs Ex-Vivo in Respiratory Drug Delivery. Invited Paper. Advanced Drug Delivery Reviews: Special Theme Issue-Computational and Visualization Approaches in Respiratory Delivery. (2012) 64 (4) March 30: 344-356. (Impact Factor: 12.888)[82]

34. Willis, M.L., Hayes, D Jr., and *Mansour, H.M.* Therapeutic Liposomal Dry Powder Inhalation Aerosols for Targeted Lung Delivery. Lung (2012) 190 (3): 251-262.(Impact Factor: 2.062)[83] [84]

35.*Mansour, H.M.* "Aerosol Formulation Issues." Pediatric Pulmonology (2012) 47 (35):149-151. (Impact Factor: 2.533) [85]


== 2013 ==

36. Meenach, S.A. Vogt,F.G., Anderson, K.W., Hilt, J.Z., McGarry,R.C., and *Mansour, H.M.*. Design, Physicochemical Characterization, and Optimization of Organic Solution Advanced Spray-Dried Inhalable Dipalmitoylphosphatidylcholine (DPPC) and Dipalmitoylphosphatidylethanolamine Poly(Ethylene Glycol) (DPPE-PEG) Microparticles and Nanoparticles for Targeted Respiratory Nanomedicine Delivery as Dry Powder Inhalation Aerosols. International Journal of Nanomedicine (2013) 8:275-293.(Impact Factor: 3.463)[86]

37. Meenach, S.A., Anderson, K.W., Hilt, J.Z., McGarry, R.C., and *Mansour, H.M.* Characterization and Aerosol Dispersion Performance of Advanced Spray-Dried Chemotherapeutic PEGylated Phospholipid Particles for Dry Powder Inhalation Delivery in Lung Cancer. European Journal of Pharmaceutical Sciences (2013) 49 (4): 699-711.(Impact Factor: 3.212)[87]

38. Wu,X., Hayes, D Jr., Zwischenberger, J.B., Kuhn, R.J., and *Mansour, H.M.* Design and Physicochemical Characterization of Advanced Spray-Dried Tacrolimus Multifunctional Particles for Inhalation. Drug Design, Development, and Therapy (2013) 7:59-72. (Impact Factor: 3.486) [88]

39. Wu,X., Zhang, W., Hayes, D Jr., and *Mansour, H.M.* Physicochemical Characterization and Aerosol Dispersion Performance of Organic Solution Advanced Spray-Dried Cyclosporine A Multifunctional Particles for Dry Powder Inhalation Aerosol Delivery. International Journal of Nanomedicine (2013) 8 :1269-1283.(Impact Factor: 3.463)[89]

40. Park, C.W., Li X., Vogt, F.G., Hayes, D. Jr., Zwischenberger, J.B., Park, E.S. and *Mansour, H.M.* Advanced Spray Dried Design, Physicochemical Characterization and Aerosol Dispersion Performance of Vancomycin and Clarithromycin Multifunctional Controlled Release Particles for Targeted Respiratory Delivery as Dry Powder Inhalation Aerosols.. International Journal of Pharmaceutics (2013) 455 (1–2): 374–392.(Impact Factor: 3.458)[90]

41. Zheng Z, Zhang W, Sun W, Li X, Duan J, Cui J, Feng Z, and *Mansour, H.M.* Influence of the Carboxymethyl Chitosan Anti-Adhesion Solution on the TGF-β1 in a Postoperative Peritoneal Adhesion Rat. Journal of Materials Science: Materials in Medicine (2013) 24 (11): 2549-2559. (Impact Factor: 2.141) [91]

42. Duan J.H., Vogt, F.G., Li X., Hayes, D. Jr., and *Mansour, H.M.* Design, Physicochemical Characterization and Aerosolization of Organic Solution Advanced Spray Dried and Co-Spray Dried Moxifloxacin and Ofloxacin Dipalmitoylphosphatidylcholine (DPPC) Microparticulate/Nanoparticulate Powders for Pulmonary Inhalation Aerosol Delivery. International Journal of Nanomedicine (2013) 8: 3489-3505. [92](Impact Factor: 3.463)

43. Hayes, D. Jr., Galantowicz, M., Yates, A.R., Preston, T.J., Mansour, H.M., and McConnell, P.I. Venovenous ECMO as a Bridge to Lung Transplant and Protective Strategy for Subsequent Primary Graft Dysfunction. Journal of Artificial Organs (2013) 16 (3): 382-385. (Impact Factor: 1.414)[93]

44. Hayes, D. Jr., Baker, P.B., Mansour, H.M., Peeples, M.E., and Nicol, K.K. Interstitial Lung Disease in a Child with Antisynthetase Syndrome. Lung (2013) 191 (4): 441-443. (Impact Factor: 2.062)[94]

45.Hayes, D. Jr., Daniels, C.J., Mansour, H.M., Kopp, B.T., Yates, A.R., McCoy, K.S., Patel, A.V., and Kirby, S. Right Heart Catherization Measuring Central Hemodynamics in Cystic Fibrosis During Exercise. Respiratory Medicine (2013): 107 (9): 1365–1369. [Impact Factor: 2.585][95]

46. Hayes, D. Jr., Daniels, C.J., Mansour, H.M., Kopp, B.T., Yates, A.R., Preston, T., and Kirby, S. Identification of the Nodose Ganglia and TRPV1 in Swine. Lung (2013): 191(5):445-447(Impact Factor: 2.062)[96]

47.Hayes, D Jr., Kirkby, S., McCoy, K.S., Mansour, H.M., Khosravi, M., Strawbridge, H., and Tobias, J.D. Reduction of Lipid-Laden Macrophage Index After Laproscopic Nissen Fundoplication in Cystic Fibrosis Patients After Lung Transplantation. Clinical Transplantation (2013) 27 (1): 121-125.(Impact Factor: 1.634) [97]


== 2014 ==

48. Hayes, D. Jr., Yates, A.R., Duffy, V., Tobias, J., Mansour, H.M., Olshove, V., and Preston, T.J. Rapid placement of bicaval dual-lumen catheter in a swine model of venovenous ECMO. Journal of Investigative Surgery (2014): 27(1):27-31. [Impact Factor: 1.316] [98]

49. Hayes, D. Jr., Adler, B., Turner, T.L., and Mansour, H.M.. Alternative Tacrolimus and Sirolimus Regimen Associated with Rapid Resolution of Posterior Reversible Encephalopathy Syndrome After Lung Transplantation. Pediatric Neurology (2014) 50: 272-275.(Impact Factor: 1.416)[99]

50. Hayes, D. Jr., Adler, B., Duffy, V., Turner, T.L., and Mansour, H.M.. Precordial Catch Syndrome in Elite Swimmers with Asthma.Pediatric Emergency Care (2014)

51. Li X., Vogt, F.G., Hayes, D. Jr., and *Mansour, H.M.* Physicochemical Characterization and Aerosol Dispersion Performance of Organic Solution Advanced Spray Dried Microparticulate/Nanoparticulate Antibiotic Dry Powders of Tobramycin and Azithromycin for Pulmonary Inhalation Aerosol Delivery. European Journal of Pharmaceutical Sciences (2014) 15: 191-205. (Impact Factor: 2.987) [100]

52. Li X., Vogt, F.G., Hayes, D. Jr., and *Mansour, H.M.* Design, Characterization, and Aerosol Dispersion Performance Modeling of Advanced Spray-Dried Microparticulate/Nanoparticulate Mannitol Powders for Targeted Pulmonary Delivery as Dry Powder Inhalers. Journal of Aerosol Medicine & Pulmonary Drug Delivery: 2013 ISAM World Congress Special Issue (2014): 27 (2):1-13. (Impact Factor: 2.894)[101]

53. Muralidharan, P., Mallory, E., Malapit, M., Hayes, D. Jr., and *Mansour, H.M.* Inhalable PEGylated Phospholipid Nanocarriers and PEGylated Therapeutics for Respiratory Delivery as Aerosolized Colloidal Dispersions and Dry Powder Inhalers. Invited Paper. Pharmaceutics: Special Issue: Liposomal Technologies (2014)[102]

54. Muralidharan, P., Malapit, M., Mallory, E., Hayes, D. Jr., and *Mansour, H.M.* Inhalable Nanoparticulate Powders for Respiratory Delivery. Invited Paper. Nanomedicine (2014)(Impact Factor: 5.26)[103]

Edited Book (co-Editor)

1. Nanomedicine in Drug Delivery, Kumar, A., Mansour, H.M., Friedman, A., and Blough, E. (Editors), First Edition, CRC Press/Taylor & Francis, London, United Kingdom. (2013) 469 pages. [104][105][106]

Book Chapters *Corresponding Author*

1. Hickey, A.J. and Mansour, H.M. Book Volume 2, Book Chapter 43: Formulation Challenges of Powders for the Delivery of Small Molecular Weight Molecules as Aerosols. Modified-Release Drug Delivery Technology, Drugs and the Pharmaceutical Sciences Series, Rathbone, M. J., Hadgraft, J., Roberts, M.S., Lane, M.E, (Editors), Second Edition, Informa Healthcare, New York, (2008): pp. 573-602. [107]

2. Hickey, A.J. and Mansour, H.M. Book Volume 2, Chapter 5: Delivery of Drugs by the Pulmonary Route. Modern Pharmaceutics Volume 2: Applications and Advances, Drugs and the Pharmaceutical Sciences Series, Florence, A.T., Siepmann, J. (Editors), Fifth Edition, Informa Healthcare, New York, (2009): 191-219. [108]

3. *Mansour, H.M.*, Rhee, Y.S., Park, C.W., and DeLuca, P.P. Book Chapter 9: Lipid Nanoparticulate Drug Delivery and Nanomedicine. Lipids in Nanotechnology. 302 pages. Moghis, A. (Editor), First Edition, American Oil Chemists Society (AOCS) Press, Urbana, Illinois (2011): pp.221-268. [109]

4. *Mansour, H.M.*, Park, C.W., and Hayes, D. Jr. Book Chapter 3: Nanoparticle Lung Delivery and Inhalation Aerosols for Targeted Pulmonary Nanomedicine. Nanomedicine in Drug Delivery. Kumar, A., Mansour, H.M., Friedman, A., Blough, E. (Editors), First Edition, CRC Press/Taylor & Francis, Inc., London, United Kingdom. (2013): pp.43-74. [110] [111][112]

5. *Mansour, H.M.*, Park, C.W., and Bawa, R. Book Chapter 6: Design and Development of Approved Nanopharmaceutical Products. Handbook of Clinical Nanomedicine: From Bench to Bedside. Bawa, R., Audette, G., and Rubinstein, I. (Editors),Pan Stanford Publishing/Taylor & Francis, Boca Raton, FL, (2014): pp. 1-27. [113]

6. *Mansour, H.M.*, Xu, Z., Meenach, S.A., Park, C.W., Rhee, Y.S., and DeLuca, P.P. Book Chapter 4: Novel Drug Delivery Systems. Drug Delivery. Mitra, A.K. (Editor), First Edition, Jones & Bartlett, Burlington, MA. (2014)IN PRESS.

7.*Mansour, H.M.*, Myrdal, P.B., Younis, U., and Hayes, D. Jr. Book Chapter 12: Pulmonary Drug Delivery. Drug Delivery & Targeting. Hillery, A.M., Swarbrick, J., and Park, K., (Editors), Second Edition, CRC Press/Taylor & Francis, Inc., London, United Kingdom. (2014).

Professional Memberships

1.Academy of Pharmaceutical Sciences of Great Britain (APSGB)

2.American Society of Nanomedicine (ASNM)

3.American Pharmacists Association (APhA)

4.American Chemical Society (ACS)

5.American Association of Pharmaceutical Scientists (AAPS)

6.American Association of the Colleges of Pharmacy (AACP)

7.Controlled Release Society (CRS)

8.European Federation for Pharmaceutical Sciences (EUFPS)

9.European Cystic Fibrosis Society (ECFS)

10.International Society for Aerosols in Medicine (ISAM)

11.The Aerosol Society

12.International Association of Colloid and Interface Scientists (IACIS)

13.Phi Eta Sigma

14.Phi Kappa Phi

15.Golden Key

16.Rho Chi Pharmaceutical Honor Society

Research Lab Group Members

1. Dr. Yun-Seok Rhee, Ph.D.,(SungKyunKwan University College of Pharmacy, S. Korea. Ph.D. Advisor: Dr. Eun-Seok Park), Postdoctoral Research Scholar. Current Position: Assistant Professor, Gyeongsang National University, S. Korea.[114]

2. Dr. Xiao Wu, Ph.D.(University of Bath College of Pharmacy, Bath, England. Ph.D. Advisor: Dr. Richard Guy), Postdoctoral Research Scholar. Current Position: Formulation Chemist, Eli Lilly Animal Health Division (Elanco), Indianapolis, IN.

3. Dr. Chun-Woong Park, Ph.D.(SungKyunKwan University College of Pharmacy, S. Korea. Ph.D. Advisor: Dr. Eun-Seok Park), Postdoctoral Research Scholar. Current Position: Assistant Professor, Chungbuk National University College of Pharmacy, S. Korea [115]

4. Dr. Jinghua Duan, Ph.D., (School of Medicine, Central South University, P.R China. Ph.D. Advisor: Dr. Jinfeng Zhao), Postdoctoral Research Scholar. Current Position: Research Associate, University of Washington-Seattle.

5. Dr. Samantha Meenach, Ph.D. (UK College of Engineering, Major Professor: Dr. Kim W. Anderson), NIH NCI CNTC Postdoctoral Fellow. Current Position: Assistant Professor of Chemical Engineering, University of Rhode Island. [116]

6. Dr. Wei Fen Zhang, M.D., Ph.D., Visiting Professor. Current Position: Associate Professor, School of Pharmaceutical & Biological Science,Weifang Medical University, Shedong, P.R. China.

7. Dr. Scott Silva, Ph.D., M.D.(UK College of Medicine, Major Professor: Dr. Mark Evers),Postdoctoral Physician-Scientist NIH CCTS PSMRF Research Fellow. Current Position: Clinical Faculty, Vanderbilt University School of Medicine.

8. Dr. Sung Gu Han, Ph.D.(UK College of Medicine, Major Professor: Dr. Gary Gairola), Postdoctoral Research Associate. Current Position, Assistant Professor, Konkuk University College of Animal Bioscience and Technology, Seoul, S. Korea. [117]

9. MinJi Sohn, M.S., Visiting Graduate Student Research Scholar

10. Xiaojian Li, M.S., Doctoral Candidate (Dissertator), Daniel P. Reedy Fellow, Quality Achievement Fellow, Center of Membrane Sciences Fellow, S. Elizabeth Helton Memorial Scholar in Pulmonary Research

11. Dr. Lauren Willis, Pharm.D. Researcher. Current Position: Clinical Faculty at MD Anderson Cancer Center

12. Priya Muralidharan, M.S.(New Jersey Institute of Technology-Pharmaceutical Engineering), Predoctoral Graduate Student & Lab Manager.

13. Monica Malapit, Pharm.D. Graduate Researcher.

14. Evan Mallory, Pharm.D. Graduate Researcher.

Co-Advisor Lab Group Members

1. Nathanael Stocke, NSF-IGERT Fellow & NIH NCI CNTC Fellow, College of Engineering[118] [119] [120]

2. Alexander McKinlay, NSF-REU Fellow, Department of Biomedical Engineering[121]

Meeting Abstracts selected from 2006-Present (over 30 abstracts prior to 2006)*Presenting Author*

National and International Meeting Abstracts

1.*Mansour, H.M.*, Damodaran, S., and Zografi, G. Surface Structural Characterization and Effects of a Surface-Active, Hydrophobic Heteropolypeptide, KL4, on Phospholipid Bilayer Spreading and Monolayer Phase Behavior at the Air-Water Interface: Implications for Pulmonary Surfactant Delivery. The 10th Annual Liposome Research Days & The 1st Univ. of North Carolina Drug Conference, Chapel Hill, NC, 2006.

2.*Mansour, H.M.*, Kujanpää, J., Tuomenoja, H., Papadopoulos, D., Mulder, T., Langridge, J., and Hickey, A.J. Characterization of the Effects of Various Sugar Carriers and Inhalation Devices on the Surface Electrostatics of Aerosolized Dry Powder Inhalation Particles containing Albuterol Sulfate. The AAPS Journal (2006) 8 (S2) M1239.

3.*Mansour, H.M.*, Kujanpää, J., Tuomenoja, H., and Hickey, A.J. Electrostatic Charge Behavior of Aerosolized Pharmaceutical Particles for Various Drug/Sugar Carrier Dry Powder Inhalation Particulate Systems. The AAPS Journal (2006) 8 (S2) M1245.

4.*Mansour, H.M.*, Xu, Z., and Hickey, A.J. Characterization of Dry Powder Aerosols of Albuterol Sulfate and Cromolyn Sodium with Various Sugar Carriers Delivered by Standardized Entrainment Tubes. The AAPS Journal (2007) 9 (S2) W5234.

5.Xu, Z., Mansour, H.M., Mulder, T., McLean, R., Langridge, J., and Hickey, A.J. Characterization of Dry Powder Aerosols of Albuterol Sulfate/Lactose Monohydrate and Cromolyn Sodium/Lactose Monohydrate Delivered by Standardized Entrainment Tubes. The AAPS Journal (2007) 9 (S2) W5235.

6.Xu, Z., Mansour, H.M., Mulder, T., McLean, R., Langridge, J., and Hickey, A.J. Performance Evaluation of Dry Powder Aerosol Formulation Using Modified Surface Adsorption Expression. The AAPS Journal (2009) (S2) R6197.

7.Xu, Z., Mansour, H.M., Mulder, T., McLean, R., Langridge, J., and Hickey, A.J. Heterogenous Particle Deaggregation and Its Implication for Therapeutic Aerosol Performance. The AAPS Journal (2009) (S2) R6198.

8.Mansour, H.M., Sohn, M., Rhee, Y.S., Woo, B., and DeLuca P.P. Sustained Release Delivery of Octreotide Acetate from Biodegradeable Polymeric Microspheres. The AAPS Journal (2009) (S2) W5036.

9.Li, X. and Mansour, H.M. Physicochemical Characterization and Water Vapor Sorption of Advanced Spray Dried Trehalose Microparticles and Nanoparticles in the Solid-State for Targeted Pulmonary Delivery as Dry Powders. Pharmaceutics Graduate Student Research Meeting (PGSRM). The Ohio State University College of Pharmacy, Columbus, OH. (June 2010).

10.Ma, J., Dziubla, T.D., and Mansour, H.M. Advanced Spray Dried Particles for Targeted Pulmonary Delivery in Lung Cancer. Pharmaceutics Graduate Student Research Meeting (PGSRM). The Ohio State University College of Pharmacy, Columbus, OH. (June 2010).

11.Wu, X. and Mansour, H.M. Advanced Spray Dried Tacrolimus Particles for Lung Transplant Immunosuppression By Targeted Dry Powder Pulmonary Inhalation Delivery. Pharmaceutics Graduate Student Research Meeting (PGSRM). The Ohio State University College of Pharmacy, Columbus, OH. (June 2010).

12.Li, X. and *Mansour, H.M.* Quality-By-Design for Excipient Functionality: Advanced Spray-Dried Trehalose Microparticles and Nanoparticles for Targeted Pulmonary Inhalation Delivery. International Pharmaceutical Excipient Council (IPEC) Excipient Fest 2011, Baltimore, MD. (Mansour, H. M. Presenting Author).

13.Park, C.W, Hayes, D. Jr., and Mansour, H.M. Advanced Spray-dried Vancomycin hydrochloride and Clarithromycin Particles for Targeted Pulmonary Inhalation Delivery as Dry Powders. Controlled Release Society Annual Meeting & Exhibition 2011 National Harbor, MD.

14.Li, X., Hayes, D. Jr, and Mansour, H.M. Advanced Spray Dried Microparticles/Nanoparticles of Antibiotics and a Mucolytic in the Solid-state for Cystic Fibrosis Treatment by Targeted Pulmonary Delivery. Controlled Release Society Annual Meeting & Exhibition 2011 National Harbor, MD.

15.Ma, J., Dziubla, T.D., and Mansour, H.M. Advanced Spray Dried Particles for Targeted Pulmonary Delivery in Lung Cancer. Controlled Release Society Annual Meeting & Exhibition 2011 National Harbor, MD.

16.*Mansour, H.M.* Rational Design, Development, and Optimization of Nanopharmaceuticals for Targeted Drug Delivery in Nanomedicine-An Interfacial and Colloidal Science Approach. 242th American Chemical Society (ACS) 2011 Annual Meeting-ACS Colloid & Surfaces Symposium on Nanomedicine.ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Volume: 242 Meeting Abstract: 281-COLL (August 2011) (Mansour, H.M. Presenting Author/Invited Speaker/Session Presider).

17.*Mansour, H.M.* Phospholipid Nanopharmaceuticals in Advanced Drug Delivery. 2011 American Oil Chemist's Society (AOCS) Annual Meeting & Exhibition, Symposium on “Phospholipids in Pharma and Cosmetics Applications", Cincinnati, OH. (Symposium Speaker).

18.Stocke, N., Mansour, H.M., and Hilt, J.Z. Enhanced Transport of PEG-Based Magnetic Nanocomposites In Artificial Mucus Barriers. 2011 American Institute of Chemical Engineers (AIChE) Annual Meeting & Exhibition, "Nanoscale Science and Engineering Forum". [122]

19. Li, X., Hayes, D. Jr, and Mansour, H.M. Advanced Spray-Dried Microparticulate/Nanoparticulate Powders for Cystic Fibrosis Treatment by Targeted Pulmonary Delivery. 2011 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting & Exhibition.

20. *Mansour, H.M.*, Park, C.W, Vogt, F.G., and Hayes, D. Jr. Advanced Spray-Dried Vancomycin Hydrochloride and Clarithromycin Lipospheres for Targeted Pulmonary Inhalation Aerosol Delivery. 4th Annual Nanotechnology & Nanomedicine Symposium.

21. *Mansour, H.M.*, Li, X, and Hayes, D. Jr. TARGETED LUNG DELIVERY BY INHALABLE MULTIFUNCTIONAL MICROPARTICULATE/NANOPARTICULATE AEROSOLS FOR CYSTIC FIBROSIS COMBINATION DRUG/MUCOLYTIC TREATMENT. Pediatric Pulmonology Journal (2011) Supplement Issue 34: 346. (presentation at the 2011 North American Cystic Fibrosis Conference (NACFC) Annual Meeting & Exhibition), Anaheim, CA (November 2011).

22. Meenach, S.A., McGarry, R.C., Hilt, J.Z., Anderson, K.W., and Mansour, H.M. Advanced Spray Dried Microparticulate/Nanoparticulate Inhalable Polymeric Lipospheres Containing Paclitaxel for Targeted Pulmonary Nanomedicine in Lung Cancer Treatment. 39th Annual Controlled Release Society (CRS) Meeting & Exhibition 2012, Quebec, Canada (July 2012).

23.Hayes, D. Jr., Yates, A.R., Duffy, V.L., Chicoine, L.G., Nicol, K.K., Mansour, H.M., McConnell, P.I., Preston, T.J. Placement of a Bicaval Dual-lumen Catheter in Piglets Using Anatomical Landmarks and Confirmation with Transthoracic Echocardiography Doppler Imaging in a Model of Single-Venous Venovenous Extracorporeal Membrane Oxygenation. CHEST 2012 Annual Meeting,Atlanta, GA. CHEST(2012) 142 (4):770A.[123]

24. Hayes, D. Jr., Kopp, B.T., Mansour, H.M., Kirkby, S., Yates, A.R., McCoy, K.S., Daniels, C.J. Exercise-induced Pulmonary Arterial Hypertension in Pediatric and Young Adult Patients with Cystic Fibrosis. CHEST 2012 Annual Meeting, Atlanta, GA. CHEST(2012) 142 (4):773A. [124]

25.Meenach, S.A., McGarry, R.C., Hilt, J.Z., Anderson, K.W., and Mansour, H.M. Characterization and Optimization of Inhalable PEGylated Phospholipid Microparticles and Nanoparticles Containing Paclitaxel for Targeted Pulmonary Nanomedicine in Lung Cancer as Dry Powder Inhalers. 2012 American Institute of Chemical Engineers (AIChE) Annual Meeting & Exhibition, Pittsburgh, PA (October 2012). [125]

26.Meenach, S.A., Tsoras, A.N., McGarry, R.C., Mansour, H.M. , Hilt, J.Z., and Anderson, K.W. Development of Three-Dimensional Lung Multicellular Spheroids in Air and Liquid Interface Culture for the Evaluation of Anti-Cancer Therapeutics. 2012 American Institute of Chemical Engineers (AIChE) Annual Meeting & Exhibition, Pittsburgh, PA (October 2012)[126]

27.Stocke, N., Meenach, S.A., Anderson, K.W., Mansour, H.M. , and Hilt, J.Z. Development of Inhalable Iron Oxide Nanocomposites for Application in Lung Cancer Therapy. 2012 American Institute of Chemical Engineers (AIChE) Annual Meeting & Exhibition, Pittsburgh, PA (October 2012)[127]

28. Stocke, N., Zhang, X., Mansour, H.M., DeRouchey, J., and Hilt, J.Z., Probe Diffusion in Poly(ethylene glycol)-based Hydrogels Studied by Fluorescence Correlation Spectroscopy. 2012 American Institute of Chemical Engineers (AIChE) Annual Meeting & Exhibition, Pittsburgh, PA (October 2012)[128]

29. Meenach, S.A., Anderson, K.W., Hilt, J.Z., McGarry, R.C., and Mansour, H.M. Characterization and Optimization of Inhalable PEGylated Phospholipid Microparticles and Nanoparticles Containing Paclitaxel for Targeted Pulmonary Nanomedicine in Lung Cancer. 2012 Society for Biomaterials Conference-Biomaterials Day, Lexington, KY (October 2012).1st Place-Best Oral Presentation Award

30. Li, X., Vogt, F.G., Hayes, D. Jr, and Mansour, H.M. Design and Aerosol Dispersion Performance of Organic Solution Advanced Spray-Dried Microparticulate/Nanoparticulate Mucolytic Powders for Targeted Pulmonary Delivery as Dry Powder Inhalers. 2012 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting & Exhibition, Chicago, IL. (October 2012)

31. Li, X., Vogt, F.G., Hayes, D. Jr, and Mansour, H.M. Design and Aerosol Dispersion Performance of Organic Solution Advanced Co-Spray-Dried Multifunctional Microparticulate/Nanoparticulate Aerosol Formulations for Targeted Pulmonary Delivery as Dry Powder Inhalers. 2012 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting & Exhibition, Chicago, IL. (October 2012)

32. Li, X., Vogt, F.G., Hayes, D. Jr, and Mansour, H.M. Design and Aerosol Dispersion Performance of Organic Solution Advanced Spray-Dried Microparticulate/Nanoparticulate Mucolytic Powders for Targeted Pulmonary Delivery as Dry Powder Inhalers in Cystic Fibrosis. Pediatric Pulmonology Journal (2012) 47: 360-361.(presentation at the 2012 North American Cystic Fibrosis Conference (NACFC) Annual Meeting, Orlando, FL.) (October 2012)

33.Mansour, H.M. Nanotechnology in Dry Powder Inhalation Aerosol Formulations. ISAM 2013 Nineteenth World Congress of the International Society for Aerosols in Medicine, Chapel Hill, NC. (April 2013)

34. Stocke, N., Meenach, S.A., Mansour, H.M., Hilt, J.Z. Formulation and Characterization of Inhalable Magnetic Nanocomposite Microparticles (MnMs) for Targeted Pulmonary Delivery. 40th Annual Controlled Release Society Meeting & Exhibition 2013, Hawaii (July 2013).

35. Meenach, S.A., Tsoras, A.N., McGarry, R.C., Mansour, H.M. , Hilt, J.Z., and Anderson, K.W. Development of Three-Dimensional Lung Multicellular Spheroids for the Evaluation of Anti-Cancer Therapeutics.40th Annual Controlled Release Society Meeting & Exhibition 2013, Hawaii (July 2013)

36.Stocke, N., Meenach, S.A., Anderson, K.W., Arnold, S., Mansour, H.M. , and Hilt, J.Z. Inhalable Magnetic Nanocomposite Microparticles for Application in Lung Cancer Therapy-In Vitro Safety and Efficacy Studies. 2013 American Institute of Chemical Engineers (AIChE) Annual Meeting & Exhibition, San Francisco, CA (November 2013)[129]

37.Hayes, D. Jr, and Mansour, H.M. Survival of Cystic Fibrosis Patients on ECHMO: Analysis. Pediatric Pulmonology Journal (2013) (presentation at the 2013 North American Cystic Fibrosis Conference (NACFC) Annual Meeting, Salt Lake City, UT)(October 2013)

38.Li, X., Vogt, F.G., Hayes, D. Jr, and Mansour, H.M. Physicochemical Characterization and Aerosol Dispersion Performance of Organic Solution Advanced Co-Spray Dried Multifunctional Microparticulate/Nanoparticulate Antimicrobial Aerosol Formulations for Targeted Pulmonary Delivery as Dry Powder Inhalers for the Treatment of Cystic Fibrosis. 2013 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting & Exhibition, San Antonio, TX. (November 2013)

39.Stocke, N., Arnold, S., Mansour, H.M. , and Hilt, J.Z. Inhalable Magnetic Nanocomposite Microparticles (MnMs)Dry Powders for Targeted Pulmonary Delivery. 2014 Society for Biomaterials(SFB) Annual Meeting & Exhibition, Denver, CO. (April 2014)[130]

Personal tools